Filed by Soaring Eagle Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Ginkgo Bioworks, Inc. Commission File No.: 333-256121 Grow with Ginkgo Anna Marie Wagner, SVP Corporate Development annamarie@ginkgobioworks.com G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Filed by Soaring Eagle Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Ginkgo Bioworks, Inc. Commission File No.: 333-256121 Grow with Ginkgo Anna Marie Wagner, SVP Corporate Development annamarie@ginkgobioworks.com G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

DIS CL AIMER Disclaimer This confidential presentation (the “presentation”) is being delivered to you by Soaring Eagle Acquisition Corp. (“SRNG”) and Ginkgo Bioworks, Inc. (“Ginkgo”) for use by Ginkgo and SRNG in connection with their proposed business combination and the offering of the securities of the post-business combination company in a private placement (the “Transaction”). This presentation is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in Ginkgo. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of its contents, without the prior consent of Ginkgo is prohibited. By accepting this presentation, each recipient agrees (on behalf of itself and each of its directors, partners, officers, employees, attorneys, financial advisors, agents and representatives (each of the foregoing, a “representative”) agrees: (i) to maintain (and direct its representatives to maintain) the confidentiality of all information that is contained in this presentation and not already in the public domain; and (ii) to return or destroy (and direct its representatives to return or destroy) all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies. Neither this presentation nor any oral statements made in connection with this presentation shall constitute an offer to sell or the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval, in any jurisdiction in connection with the proposed business combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No Representations or Warranties This presentation is for informational purposes only and does not purport to contain all of the information that may be required to evaluate a possible investment decision with respect to Ginkgo. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. No representation or warranty, express or implied, is or will be given by SRNG or Ginkgo or any of their respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation of a possible transaction between SRNG and Ginkgo and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. SRNG and Ginkgo disclaim any duty to update the information contained in this presentation. Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SRNG’s and Ginkgo’s actual results may differ from their expectations, estimates and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, SRNG’s and Ginkgo’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of closing conditions to the Transaction and the timing of the completion of the Transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of SRNG’s registration statement on Form S-1. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the Transaction, which is expected to be filed by Ginkgo with the Securities and Exchange Commission (the “SEC”), and other documents filed by SRNG from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside SRNG’s and Ginkgo’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against SRNG or Ginkgo following the announcement of the Transaction; (2) the inability to complete the Transaction, including due to the inability to concurrently close the business combination and the private placement of common stock or due to failure to obtain approval of the stockholders of SRNG; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals, or delays in completing regulatory reviews, required to complete the Transaction; (4) the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; (5) the inability to recognize the anticipated benefits of the Transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (6) costs related to the Transaction; (7) changes in the applicable laws or regulations; (8) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) the risks described in the Appendix hereto; and (11) other risks and uncertainties indicated from time to time described in SRNG’s registration on Form S-1, including those under “Risk Factors” therein, and in SRNG’s other filings with the SEC. SRNG and Ginkgo caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Neither SRNG nor Ginkgo undertakes or accepts any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Industry and Market Data In this presentation, SRNG and Ginkgo rely on and refer to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo’s management’s estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information. Neither Ginkgo nor SRNG has independently verified the accuracy or completeness of the information provided by the third-party sources. 2DIS CL AIMER Disclaimer This confidential presentation (the “presentation”) is being delivered to you by Soaring Eagle Acquisition Corp. (“SRNG”) and Ginkgo Bioworks, Inc. (“Ginkgo”) for use by Ginkgo and SRNG in connection with their proposed business combination and the offering of the securities of the post-business combination company in a private placement (the “Transaction”). This presentation is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in Ginkgo. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of its contents, without the prior consent of Ginkgo is prohibited. By accepting this presentation, each recipient agrees (on behalf of itself and each of its directors, partners, officers, employees, attorneys, financial advisors, agents and representatives (each of the foregoing, a “representative”) agrees: (i) to maintain (and direct its representatives to maintain) the confidentiality of all information that is contained in this presentation and not already in the public domain; and (ii) to return or destroy (and direct its representatives to return or destroy) all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies. Neither this presentation nor any oral statements made in connection with this presentation shall constitute an offer to sell or the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval, in any jurisdiction in connection with the proposed business combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No Representations or Warranties This presentation is for informational purposes only and does not purport to contain all of the information that may be required to evaluate a possible investment decision with respect to Ginkgo. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. No representation or warranty, express or implied, is or will be given by SRNG or Ginkgo or any of their respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation of a possible transaction between SRNG and Ginkgo and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. SRNG and Ginkgo disclaim any duty to update the information contained in this presentation. Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SRNG’s and Ginkgo’s actual results may differ from their expectations, estimates and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, SRNG’s and Ginkgo’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of closing conditions to the Transaction and the timing of the completion of the Transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of SRNG’s registration statement on Form S-1. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the Transaction, which is expected to be filed by Ginkgo with the Securities and Exchange Commission (the “SEC”), and other documents filed by SRNG from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside SRNG’s and Ginkgo’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against SRNG or Ginkgo following the announcement of the Transaction; (2) the inability to complete the Transaction, including due to the inability to concurrently close the business combination and the private placement of common stock or due to failure to obtain approval of the stockholders of SRNG; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals, or delays in completing regulatory reviews, required to complete the Transaction; (4) the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; (5) the inability to recognize the anticipated benefits of the Transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (6) costs related to the Transaction; (7) changes in the applicable laws or regulations; (8) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) the risks described in the Appendix hereto; and (11) other risks and uncertainties indicated from time to time described in SRNG’s registration on Form S-1, including those under “Risk Factors” therein, and in SRNG’s other filings with the SEC. SRNG and Ginkgo caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Neither SRNG nor Ginkgo undertakes or accepts any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Industry and Market Data In this presentation, SRNG and Ginkgo rely on and refer to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo’s management’s estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information. Neither Ginkgo nor SRNG has independently verified the accuracy or completeness of the information provided by the third-party sources. 2

DIS CL AIMER Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and SRNG’s and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but SRNG and Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Private Placement The securities to which this presentation relate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that SRNG intends to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense. Financial Information This presentation contains certain estimated preliminary financial results and key operating metrics for the year ended December 31, 2020, and the historical financial information with respect to Ginkgo contained in this presentation has been taken from or prepared based on historical financial statements of Ginkgo, including unaudited financial statements for its fiscal year ended December 31, 2020. This information is preliminary and subject to adjustment in connection with the completion of the audit for the fiscal year ended December 31, 2020. As such, Ginkgo’s actual results and financial condition as reflected in the financial statements that will be included in the proxy statement/prospectus on Form S-4 for the proposed Transaction may be adjusted or presented differently from the historical financial information herein, and the variations could be material. Non-GAAP Financial Measures Certain of the financial measures included in this presentation, including Foundry Billable Revenue, Foundry Billable Revenue Growth, Net Present Value (NPV) and Adjusted EBITDA, have not been prepared in accordance with general accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures (including on a forward-looking basis) because it believes they provide an additional tool for investors to use in evaluating the financial performance and prospects of Ginkgo or any successor entity in the Transaction. These non-GAAP financial measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the Appendix for a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures. Note however, that to the extent forward-looking non-GAAP financial measures are provided herein, they are not reconciled to comparable forward-looking GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Use of Projections This presentation also contains certain financial forecasts, including projected Foundry Billable Revenue, Foundry Billable Revenue Growth, Foundry Revenue (GAAP), Biosecurity Revenue, Total GAAP Revenue, Adjusted EBITDA and CapEx. Neither SRNG’s nor Ginkgo’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and, accordingly, neither of them have expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. In this presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Projections are inherently uncertain due to a number of factors outside of SRNG’s or Ginkgo’s control. While all financial projections, estimates and targets are necessarily speculative, SRNG and Ginkgo believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. Participation in Solicitation SRNG and Ginkgo and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies of SRNG’s shareholders in connection with the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of SRNG’s directors and officers in SRNG’s filings with the SEC, including SRNG’s registration statement on Form S-1, which was originally filed with the SEC on December 23, 2020. To the extent that holdings of SRNG’s securities have changed from the amounts reported in SRNG’s registration statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SRNG’s shareholders in connection with the proposed Transaction will be set forth in the proxy statement/prospectus on Form S-4 for the proposed Transaction, which is expected to be filed by SRNG with the SEC. Investors and security holders of SRNG and Ginkgo are urged to read the proxy statement/prospectus and other relevant documents that will be filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed Transaction. Investors and security holders will be able to obtain free copies of the proxy statement and other documents containing important information about SRNG and Ginkgo through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by SRNG can be obtained free of charge by directing a written request to SRNG, 955 Fifth Avenue, New York, NY 10075. 3DIS CL AIMER Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and SRNG’s and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but SRNG and Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Private Placement The securities to which this presentation relate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that SRNG intends to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense. Financial Information This presentation contains certain estimated preliminary financial results and key operating metrics for the year ended December 31, 2020, and the historical financial information with respect to Ginkgo contained in this presentation has been taken from or prepared based on historical financial statements of Ginkgo, including unaudited financial statements for its fiscal year ended December 31, 2020. This information is preliminary and subject to adjustment in connection with the completion of the audit for the fiscal year ended December 31, 2020. As such, Ginkgo’s actual results and financial condition as reflected in the financial statements that will be included in the proxy statement/prospectus on Form S-4 for the proposed Transaction may be adjusted or presented differently from the historical financial information herein, and the variations could be material. Non-GAAP Financial Measures Certain of the financial measures included in this presentation, including Foundry Billable Revenue, Foundry Billable Revenue Growth, Net Present Value (NPV) and Adjusted EBITDA, have not been prepared in accordance with general accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures (including on a forward-looking basis) because it believes they provide an additional tool for investors to use in evaluating the financial performance and prospects of Ginkgo or any successor entity in the Transaction. These non-GAAP financial measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the Appendix for a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures. Note however, that to the extent forward-looking non-GAAP financial measures are provided herein, they are not reconciled to comparable forward-looking GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Use of Projections This presentation also contains certain financial forecasts, including projected Foundry Billable Revenue, Foundry Billable Revenue Growth, Foundry Revenue (GAAP), Biosecurity Revenue, Total GAAP Revenue, Adjusted EBITDA and CapEx. Neither SRNG’s nor Ginkgo’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and, accordingly, neither of them have expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. In this presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Projections are inherently uncertain due to a number of factors outside of SRNG’s or Ginkgo’s control. While all financial projections, estimates and targets are necessarily speculative, SRNG and Ginkgo believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. Participation in Solicitation SRNG and Ginkgo and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies of SRNG’s shareholders in connection with the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of SRNG’s directors and officers in SRNG’s filings with the SEC, including SRNG’s registration statement on Form S-1, which was originally filed with the SEC on December 23, 2020. To the extent that holdings of SRNG’s securities have changed from the amounts reported in SRNG’s registration statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SRNG’s shareholders in connection with the proposed Transaction will be set forth in the proxy statement/prospectus on Form S-4 for the proposed Transaction, which is expected to be filed by SRNG with the SEC. Investors and security holders of SRNG and Ginkgo are urged to read the proxy statement/prospectus and other relevant documents that will be filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed Transaction. Investors and security holders will be able to obtain free copies of the proxy statement and other documents containing important information about SRNG and Ginkgo through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by SRNG can be obtained free of charge by directing a written request to SRNG, 955 Fifth Avenue, New York, NY 10075. 3

Our Mission Make biology easier to engineer 4 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Our Mission Make biology easier to engineer 4 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

2006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” We can program cells (DNA) like we program computers (code) 2019 5 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 20212006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” We can program cells (DNA) like we program computers (code) 2019 5 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Combining an industry-defining founding team with proven executives who have built iconic public companies Founding team has been working together for nearly 20 years Soaring Eagle brings a track record of success in SPACs Harry Sloan Jeff Sagansky Eli Baker Reshma Shetty Jason Kelly CEO, Chairman Partner President, CFO COO CEO Arie Belldegrun with Founder, Fmr CEO/Chairman, Kite Pharma Founder, Chairman, Allogene Barry Canton Austin Che Tom Knight CTO Strategy DNA Hacker With long-term support from a deeply experienced, industry-leading independent board Marijn Dekkers Christian Henry Shyam Sankar Chairman, Governance/Nominating Chair Audit Committee Chair Compensation Committee Chair Board member since 2019 Board member since 2016 Board member since 2016 Fmr Chairman, Unilever (NYSE:UL) President/CEO, PacBio (Nasdaq:PACB) COO, Palantir (NYSE: PLTR) Fmr CEO, Bayer (XTRA:BAYN) Fmr CFO/CCO, Illumina (Nasdaq:ILMN) Fmr CEO, Thermo Fisher (NYSE:TMO) 6 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Combining an industry-defining founding team with proven executives who have built iconic public companies Founding team has been working together for nearly 20 years Soaring Eagle brings a track record of success in SPACs Harry Sloan Jeff Sagansky Eli Baker Reshma Shetty Jason Kelly CEO, Chairman Partner President, CFO COO CEO Arie Belldegrun with Founder, Fmr CEO/Chairman, Kite Pharma Founder, Chairman, Allogene Barry Canton Austin Che Tom Knight CTO Strategy DNA Hacker With long-term support from a deeply experienced, industry-leading independent board Marijn Dekkers Christian Henry Shyam Sankar Chairman, Governance/Nominating Chair Audit Committee Chair Compensation Committee Chair Board member since 2019 Board member since 2016 Board member since 2016 Fmr Chairman, Unilever (NYSE:UL) President/CEO, PacBio (Nasdaq:PACB) COO, Palantir (NYSE: PLTR) Fmr CEO, Bayer (XTRA:BAYN) Fmr CFO/CCO, Illumina (Nasdaq:ILMN) Fmr CEO, Thermo Fisher (NYSE:TMO) 6 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Cell programming is increasingly impacting our lives Ginkgo’s work to close raw material gaps in the mRNA vaccine supply chain was recently featured on 60 Minutes Vaccines are developed and manufactured using cell programming tools 7 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Cell programming is increasingly impacting our lives Ginkgo’s work to close raw material gaps in the mRNA vaccine supply chain was recently featured on 60 Minutes Vaccines are developed and manufactured using cell programming tools 7 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Cell programming is addressing our most challenging environmental and social issues Food & Agriculture Industrials & Environment Consumer & Technology Pharma & Biotech Nucleic acid Wastewater Renewable Animal protein Sugar Plant extracts: Haircare and Antibody vaccine remediation chemicals replacement reduction flavors, skincare therapeutic production fragrances, proteins development cannabinoids Textiles and Antibiotic Sustainable Brewing & Fertilizer Microbiome PFAS dyes Skin discovery and building baking reduction therapeutics degradation microbiome manufacturing materials (protection Electronic Carbon Pest control Animal feed and Gene and cell and beauty) coatings sequestration aquaculture therapies and we’re just getting started… Read “Anatomy of an Read “Redesigning Read “Ingredient Read “Microscopic Underground Wildfire” on Grow the Banana” on Grow Revolution” on Grow Doctors” on Grow 8 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Cell programming is addressing our most challenging environmental and social issues Food & Agriculture Industrials & Environment Consumer & Technology Pharma & Biotech Nucleic acid Wastewater Renewable Animal protein Sugar Plant extracts: Haircare and Antibody vaccine remediation chemicals replacement reduction flavors, skincare therapeutic production fragrances, proteins development cannabinoids Textiles and Antibiotic Sustainable Brewing & Fertilizer Microbiome PFAS dyes Skin discovery and building baking reduction therapeutics degradation microbiome manufacturing materials (protection Electronic Carbon Pest control Animal feed and Gene and cell and beauty) coatings sequestration aquaculture therapies and we’re just getting started… Read “Anatomy of an Read “Redesigning Read “Ingredient Read “Microscopic Underground Wildfire” on Grow the Banana” on Grow Revolution” on Grow Doctors” on Grow 8 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying Each new program drives We believe Ginkgo’s Each new program adds technology can be used platform improvements, ecosystem of services will predictable near-term to create applications leading to more demand. make us the obvious revenue from usage fees across all physical goods partner in the enormous, and provides Ginkgo industries. Ginkgo is the and largely untapped, upside through value first horizontal platform in market for cell share. this industry, supporting programming. all end markets. 9 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying Each new program drives We believe Ginkgo’s Each new program adds technology can be used platform improvements, ecosystem of services will predictable near-term to create applications leading to more demand. make us the obvious revenue from usage fees across all physical goods partner in the enormous, and provides Ginkgo industries. Ginkgo is the and largely untapped, upside through value first horizontal platform in market for cell share. this industry, supporting programming. all end markets. 9 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying technology can be used to create applications across all physical goods industries. Ginkgo is the first horizontal platform in this industry, supporting all end markets. 10 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying technology can be used to create applications across all physical goods industries. Ginkgo is the first horizontal platform in this industry, supporting all end markets. 10 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

PROGRAM LAYER Ginkgo provides program management and technical execution to product companies across all industries LEARN MORE PLATFORM LAYER Ginkgo is building the leading horizontal platform for Ginkgo is the interface cell programming across all industries between a series of complex technologies and a customer spec LEARN MORE TECHNOLOGY LAYER Ginkgo integrates standard hardware and wraps it in proprietary software and automation 11 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021PROGRAM LAYER Ginkgo provides program management and technical execution to product companies across all industries LEARN MORE PLATFORM LAYER Ginkgo is building the leading horizontal platform for Ginkgo is the interface cell programming across all industries between a series of complex technologies and a customer spec LEARN MORE TECHNOLOGY LAYER Ginkgo integrates standard hardware and wraps it in proprietary software and automation 11 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We program cells for our customers so they can develop new products 12 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We program cells for our customers so they can develop new products 12 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Over 70 major customer programs across diverse industries have run on our platform = DIVERSIFIED PLATFORM Cumulative Major 3rd Party Programs Can respond rapidly to emerging opportunities and global threats 80 + PHARMA & BIOTECH Mammalian capabilities & PRE-2015: GOVERNMENT PROGRAMS Synlogic partnership First 5+ years of technology building 60 funded through non-dilutive government programs (DARPA, SBIR, etc.) + FOOD & NUTRITION Motif (Louis Dreyfus and Fonterra) launches portfolio of animal-free protein programs + AGRICULTURE Selection by Bayer for 40 agriculture JV after significant industry vetting + INDUSTRIAL & ENVIRONMENT Experience in flavors & fragrances enabled expansion into industrial chemicals 20 CONSUMER & TECHNOLOGY Early experimentation making fine chemicals for flavors & fragrances 0 2015 2016 2017 2018 2019 2020 Consumer & Technology Industrial & Environment Agriculture Food & Nutrition Pharma & Biotech Government & Defense Note: “Major” programs exclude proof of concept work and ancillary projects and typically have at least $500K actual / expected development costs on behalf of a customer 13 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Over 70 major customer programs across diverse industries have run on our platform = DIVERSIFIED PLATFORM Cumulative Major 3rd Party Programs Can respond rapidly to emerging opportunities and global threats 80 + PHARMA & BIOTECH Mammalian capabilities & PRE-2015: GOVERNMENT PROGRAMS Synlogic partnership First 5+ years of technology building 60 funded through non-dilutive government programs (DARPA, SBIR, etc.) + FOOD & NUTRITION Motif (Louis Dreyfus and Fonterra) launches portfolio of animal-free protein programs + AGRICULTURE Selection by Bayer for 40 agriculture JV after significant industry vetting + INDUSTRIAL & ENVIRONMENT Experience in flavors & fragrances enabled expansion into industrial chemicals 20 CONSUMER & TECHNOLOGY Early experimentation making fine chemicals for flavors & fragrances 0 2015 2016 2017 2018 2019 2020 Consumer & Technology Industrial & Environment Agriculture Food & Nutrition Pharma & Biotech Government & Defense Note: “Major” programs exclude proof of concept work and ancillary projects and typically have at least $500K actual / expected development costs on behalf of a customer 13 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Market defining customers have validated the platform across a wide range of end markets Industrials CONSUMER & TECH INDUSTRIALS & ENVIRONMENT AGRICULTURE FOOD & NUTRITION PHARMA & BIOTECH Fragrances Commodities & Specialty Chemicals Fertilizers & Crop Animal-free proteins Microbiome Therapeutics (G4, G41, G53) (G15, G24, G48, G51, G90, G101, G116, Enhancement (G114, G121, G122, G128, G136, G162) (G40, G83, G139, G143, G147, G150, G152) Cannabinoids G127, G134, G142, G159) (G50, G81, G133) Flavors & Sweeteners Biologics & Gene Therapy (G102, G123) Textiles Crop Protection (G49, G56, G125, G174) (G66, G70, G115, G185) Insect Repellent (G36) (G99, G119, G132, G151, G163, Nutrition Antibiotics & APIs (G166) Environment G165) (G35, G69, G109) (G21, G67, G72, G86, G111) High-tech electronics (G131, G138, G145, G153, G164, G171) Animal Feed Brewing & Baking COVID Vaccines & Therapeutics (G37, G43) (G16, G68, G71, G146) (G52, G95, G97) (G155, G157, G158, G163, G165, G169, G170) Note: Reflects a portion of current / completed programs; program codes have been anonymized 14 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Market defining customers have validated the platform across a wide range of end markets Industrials CONSUMER & TECH INDUSTRIALS & ENVIRONMENT AGRICULTURE FOOD & NUTRITION PHARMA & BIOTECH Fragrances Commodities & Specialty Chemicals Fertilizers & Crop Animal-free proteins Microbiome Therapeutics (G4, G41, G53) (G15, G24, G48, G51, G90, G101, G116, Enhancement (G114, G121, G122, G128, G136, G162) (G40, G83, G139, G143, G147, G150, G152) Cannabinoids G127, G134, G142, G159) (G50, G81, G133) Flavors & Sweeteners Biologics & Gene Therapy (G102, G123) Textiles Crop Protection (G49, G56, G125, G174) (G66, G70, G115, G185) Insect Repellent (G36) (G99, G119, G132, G151, G163, Nutrition Antibiotics & APIs (G166) Environment G165) (G35, G69, G109) (G21, G67, G72, G86, G111) High-tech electronics (G131, G138, G145, G153, G164, G171) Animal Feed Brewing & Baking COVID Vaccines & Therapeutics (G37, G43) (G16, G68, G71, G146) (G52, G95, G97) (G155, G157, G158, G163, G165, G169, G170) Note: Reflects a portion of current / completed programs; program codes have been anonymized 14 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Ginkgo’s platform is exploring diverse applications with a broad range of partners Microbial Hosts Mammalian Hosts MAJOR PHARMA Enzyme Living Antibody Gene Discovery Therapeutics Therapeutics Therapy MULTIPLE PARTNERS Bio-process Antibiotics Optimization Discovery Animal Bio-agriculture Protein Circuits Industrial Plant Enzymes Extracts 15 Therapeutics & Non-Therapeutics Vaccines G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo’s platform is exploring diverse applications with a broad range of partners Microbial Hosts Mammalian Hosts MAJOR PHARMA Enzyme Living Antibody Gene Discovery Therapeutics Therapeutics Therapy MULTIPLE PARTNERS Bio-process Antibiotics Optimization Discovery Animal Bio-agriculture Protein Circuits Industrial Plant Enzymes Extracts 15 Therapeutics & Non-Therapeutics Vaccines G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Ginkgo’s platform has broad capabilities to accelerate and expand therapeutics discovery and manufacturing EXAMPLE CAPABILITIES EXAMPLE APPLICATIONS Enzyme Discovery & Strain Improvement Antibody & Therapeutics Optimization Our platform is well-suited to address problems HT Car Antigen Design & that require large- Cassette Design & Vaccines Selection Expression scale, systematic, and model-driven exploration of HT Antibody Engineered Disease genetic design Selection & Gene-coded Therapeutics Models spaces Optimization Synthetic Promoter and Logic-gate Cell Based Therapies Engineered Mammalian Cells 16 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo’s platform has broad capabilities to accelerate and expand therapeutics discovery and manufacturing EXAMPLE CAPABILITIES EXAMPLE APPLICATIONS Enzyme Discovery & Strain Improvement Antibody & Therapeutics Optimization Our platform is well-suited to address problems HT Car Antigen Design & that require large- Cassette Design & Vaccines Selection Expression scale, systematic, and model-driven exploration of HT Antibody Engineered Disease genetic design Selection & Gene-coded Therapeutics Models spaces Optimization Synthetic Promoter and Logic-gate Cell Based Therapies Engineered Mammalian Cells 16 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

R&D spending alone accounts for nearly $40B in untapped demand Existing market for cell engineering lab operations ($B) $60 $58B Cell Engineering Labor Cell Engineering Tools $48B $50 Our scale $22 dramatically reduces costs $40B $40 $18 $33B This market represents $15 $28B $30 over 20,000+ potential $12 (1) new cell programs $10 We bring $20 $36 efficiency to $30 scientists at the $25 bench $21 $10 $17 $0 2019 2020E 2021E 2022E 2023E Source: Piper Sandler Research (1) Assumes approximately $2M annual expense per program, in line with current average annual spend per program at Ginkgo 17 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021R&D spending alone accounts for nearly $40B in untapped demand Existing market for cell engineering lab operations ($B) $60 $58B Cell Engineering Labor Cell Engineering Tools $48B $50 Our scale $22 dramatically reduces costs $40B $40 $18 $33B This market represents $15 $28B $30 over 20,000+ potential $12 (1) new cell programs $10 We bring $20 $36 efficiency to $30 scientists at the $25 bench $21 $10 $17 $0 2019 2020E 2021E 2022E 2023E Source: Piper Sandler Research (1) Assumes approximately $2M annual expense per program, in line with current average annual spend per program at Ginkgo 17 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

$2 to $4 trillion emerging market for bioengineered products Annual Direct Economic Impact By Domain 2030—2040 (partial estimate) $1.2T $1.2T High Estimate Low Estimate Programming + significant secondary effects not measured biology is to the physical world what $700B programming computers is to the information economy $300B $300B $500B $800B $200B $200B $100B Food & Materials & Health Consumer Other Agriculture Energy Source: McKinsey Global Institute; The Bio Revolution: Innovations transforming economies, societies, and our lives (May 13, 2020) Note: these estimates reflect the estimated biotechnology penetration of these end-markets 18 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021$2 to $4 trillion emerging market for bioengineered products Annual Direct Economic Impact By Domain 2030—2040 (partial estimate) $1.2T $1.2T High Estimate Low Estimate Programming + significant secondary effects not measured biology is to the physical world what $700B programming computers is to the information economy $300B $300B $500B $800B $200B $200B $100B Food & Materials & Health Consumer Other Agriculture Energy Source: McKinsey Global Institute; The Bio Revolution: Innovations transforming economies, societies, and our lives (May 13, 2020) Note: these estimates reflect the estimated biotechnology penetration of these end-markets 18 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program drives platform improvements, leading to more demand. 19 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program drives platform improvements, leading to more demand. 19 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

The Foundry - Ginkgo’s physical infrastructure - drives a strong scale economic BW5 Lab-scale automation and significantly increased NGS capacity BW4 Added mammalian cell engineering capabilities BW3 Created scale modules by function KNIGHT’S LAW – our scale theory (e.g. DNA synthesis, -omics, BW2 sequencing, fermentation, etc.) “The cost to genetically engineer a cell decreases by 50% and the number of designs tested increases by BW1 3X+ per year in Ginkgo’s automated cell programming Early stages of building higher scale workflows and testing foundries.” automated techniques 20 2012 2016 2018 2019 2020 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021The Foundry - Ginkgo’s physical infrastructure - drives a strong scale economic BW5 Lab-scale automation and significantly increased NGS capacity BW4 Added mammalian cell engineering capabilities BW3 Created scale modules by function KNIGHT’S LAW – our scale theory (e.g. DNA synthesis, -omics, BW2 sequencing, fermentation, etc.) “The cost to genetically engineer a cell decreases by 50% and the number of designs tested increases by BW1 3X+ per year in Ginkgo’s automated cell programming Early stages of building higher scale workflows and testing foundries.” automated techniques 20 2012 2016 2018 2019 2020 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Ginkgo’s Foundry is scaling roughly 3x per year L AB OPER ATIONS: MEASURING WORK DONE ON THE PLATFORM STR AIN TESTS: MEASURING THE OUTPUT OF THE PLATFORM 1,000,000 10,000,000 1,000,000 100,000 100,000 3-4x annual increase pre-COVID 10,000 10,000 1,000 1,000 2-3x annual increase pre-COVID 100 100 10 2014 2015 2016 2017 2018 2019 2020 2021 2015 2016 2017 2018 2019 2020 2021 21 Daily Lab Operations Daily Strain Tests G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo’s Foundry is scaling roughly 3x per year L AB OPER ATIONS: MEASURING WORK DONE ON THE PLATFORM STR AIN TESTS: MEASURING THE OUTPUT OF THE PLATFORM 1,000,000 10,000,000 1,000,000 100,000 100,000 3-4x annual increase pre-COVID 10,000 10,000 1,000 1,000 2-3x annual increase pre-COVID 100 100 10 2014 2015 2016 2017 2018 2019 2020 2021 2015 2016 2017 2018 2019 2020 2021 21 Daily Lab Operations Daily Strain Tests G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Unit costs to program cells have decreased by 50% per year $10,000 $1,000 FOUNDRY IS 5-10X CHEAPER THAN THE STATUS QUO ESTIMATED “BY HAND” COST $100 BY 2025, WE SHOULD BE TWO ORDERS OF MAGNITUDE MORE EFFICIENT THAN “BY HAND” COVID impact $10 $1 2015 2016 2017 2018 2019 2020 2021 2025 Note: Costs include all operational and R&D-related activities (i.e. both current programs and investments in future capacity) 22 Cost per Strain Test (rolling 3mo avg) G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Unit costs to program cells have decreased by 50% per year $10,000 $1,000 FOUNDRY IS 5-10X CHEAPER THAN THE STATUS QUO ESTIMATED “BY HAND” COST $100 BY 2025, WE SHOULD BE TWO ORDERS OF MAGNITUDE MORE EFFICIENT THAN “BY HAND” COVID impact $10 $1 2015 2016 2017 2018 2019 2020 2021 2025 Note: Costs include all operational and R&D-related activities (i.e. both current programs and investments in future capacity) 22 Cost per Strain Test (rolling 3mo avg) G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Codebase - Ginkgo’s scale data asset - is a source of long-term competitive advantage unique gene sequences pulled 3.4B+ from all public databases proprietary gene sequences acquired 440M And growing… codebase accumulates as we run new experiments in the foundry and build new: “Ginkgo will organize the world’s biological code and make it useful.” -GINKGO HE AD OF CODEBA SE, PATRICK BOYLE Organisms Genetic Code Biological Tools 23 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Codebase - Ginkgo’s scale data asset - is a source of long-term competitive advantage unique gene sequences pulled 3.4B+ from all public databases proprietary gene sequences acquired 440M And growing… codebase accumulates as we run new experiments in the foundry and build new: “Ginkgo will organize the world’s biological code and make it useful.” -GINKGO HE AD OF CODEBA SE, PATRICK BOYLE Organisms Genetic Code Biological Tools 23 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

IMAGE CREDIT: KAREN INGRAM We design codebase when C AT T LE (BEEF & DAIRY ) INDUS T RY: working on programs (1) $1 trillion global market (2) 9% of global greenhouse gas emissions Organisms like yeast (shown above) are the biological factories for producing a wide range of molecules (1) Source: imarc Group (February 2020) and Grandview Research (January 2019) (2) Source: Barclays Research (April 2019) 24 (1) Note targets are illustrative as Motif has not announced specific products. C OD EB A S E (1) EGG PROTEINS (1) ME AT PROTEINS (1) DAIRY PROTEINS G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021IMAGE CREDIT: KAREN INGRAM We design codebase when C AT T LE (BEEF & DAIRY ) INDUS T RY: working on programs (1) $1 trillion global market (2) 9% of global greenhouse gas emissions Organisms like yeast (shown above) are the biological factories for producing a wide range of molecules (1) Source: imarc Group (February 2020) and Grandview Research (January 2019) (2) Source: Barclays Research (April 2019) 24 (1) Note targets are illustrative as Motif has not announced specific products. C OD EB A S E (1) EGG PROTEINS (1) ME AT PROTEINS (1) DAIRY PROTEINS G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We re-use codebase across programs to improve outcomes and efficiency z C OD EB A S E The SAME YEAST used to generate proteins for food can produce proteins used in personal care products, such as collagen, elastin, and keratin 25 (1) Note targets are illustrative as Kalo has not announced specific products. G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We re-use codebase across programs to improve outcomes and efficiency z C OD EB A S E The SAME YEAST used to generate proteins for food can produce proteins used in personal care products, such as collagen, elastin, and keratin 25 (1) Note targets are illustrative as Kalo has not announced specific products. G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Ginkgo’s virtuous cycle drives platform growth 26 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo’s virtuous cycle drives platform growth 26 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We believe Ginkgo’s ecosystem of services will make us the obvious partner in the enormous, and largely untapped, market for cell programming. 27 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We believe Ginkgo’s ecosystem of services will make us the obvious partner in the enormous, and largely untapped, market for cell programming. 27 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Our ecosystem will soon support hundreds of new cell programs a year 600 508 500 Self-Service Portals 400 Ecosystem Support 300 268 Still only 1-2% Platform Scaling of the market for 200 cell engineering (1) R&D services 136 Expand within Base 100 Leverage Proof Points 60 23 17 0 2020A 2021E 2022P 2023P 2024P 2025P (1) Source: Piper Sandler Research; assumes each program is approximately $2M per year of cell engineering spend and growth estimate of 0% and 20% 28 New Programs by Year G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Our ecosystem will soon support hundreds of new cell programs a year 600 508 500 Self-Service Portals 400 Ecosystem Support 300 268 Still only 1-2% Platform Scaling of the market for 200 cell engineering (1) R&D services 136 Expand within Base 100 Leverage Proof Points 60 23 17 0 2020A 2021E 2022P 2023P 2024P 2025P (1) Source: Piper Sandler Research; assumes each program is approximately $2M per year of cell engineering spend and growth estimate of 0% and 20% 28 New Programs by Year G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Each new cell program can accelerate adoption within new markets and lead to further sales with existing customers Ability to grow significantly within existing Early proof points within an industry customer accounts can lead to follow-on demand 12 10 (1) Major Program Minor Program Proof of Concept 8 6 [CONFIDENTIAL] 4 In advanced discussions with leading pharmaceutical contract manufacturer 2 [CONFIDENTIAL] Optimizing pDNA production 0 for another nucleic acid Year 1 Year 2 Year 3 Year 4 Year 5 vaccine company (1) Major programs typically incur well over $500K of annual R&D spending, minor programs are typically smaller add-on programs that have less than $500K of annual R&D spend, proof-of-concept programs are typically small programs that are often set up as a business development effort 29 # of Active Programs / Yr (Customer X) G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Each new cell program can accelerate adoption within new markets and lead to further sales with existing customers Ability to grow significantly within existing Early proof points within an industry customer accounts can lead to follow-on demand 12 10 (1) Major Program Minor Program Proof of Concept 8 6 [CONFIDENTIAL] 4 In advanced discussions with leading pharmaceutical contract manufacturer 2 [CONFIDENTIAL] Optimizing pDNA production 0 for another nucleic acid Year 1 Year 2 Year 3 Year 4 Year 5 vaccine company (1) Major programs typically incur well over $500K of annual R&D spending, minor programs are typically smaller add-on programs that have less than $500K of annual R&D spend, proof-of-concept programs are typically small programs that are often set up as a business development effort 29 # of Active Programs / Yr (Customer X) G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Strong 2021 sales pipeline with mix of new customers and expanded relationships [CONFIDENTIAL] Kalo Launched a new spin-out in personal New relationship with Biogen to New relationship with top 5 agchem New multi-product collaboration with top global care space, with strategic and financial develop a next-generation AAV company, focused on discovery and flavors & fragrances customer, building on investors production platform development of crop protection agents successful historical program execution 100 95+ [key expansion areas] 6 ~23 PROB. ADJ. 9 Crop protection Sugar reduction Renewable Recycling Protein 13 feedstocks availability and Wastewater functionality remediation 50 13 Cell & gene Pulp/Paper therapy Skin 73 Antibodies microbiome 17 Nucleic acid Sustainability therapeutics Antibiotic manufacturing 15 0 Consumer & Technology Industrial Agriculture Pharma & Biotech Food & Nutrition Government & Defense Cumulative Historical + 2021 All Historical Programs 2021 30 Number of “Major” Pipeline Programs G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Strong 2021 sales pipeline with mix of new customers and expanded relationships [CONFIDENTIAL] Kalo Launched a new spin-out in personal New relationship with Biogen to New relationship with top 5 agchem New multi-product collaboration with top global care space, with strategic and financial develop a next-generation AAV company, focused on discovery and flavors & fragrances customer, building on investors production platform development of crop protection agents successful historical program execution 100 95+ [key expansion areas] 6 ~23 PROB. ADJ. 9 Crop protection Sugar reduction Renewable Recycling Protein 13 feedstocks availability and Wastewater functionality remediation 50 13 Cell & gene Pulp/Paper therapy Skin 73 Antibodies microbiome 17 Nucleic acid Sustainability therapeutics Antibiotic manufacturing 15 0 Consumer & Technology Industrial Agriculture Pharma & Biotech Food & Nutrition Government & Defense Cumulative Historical + 2021 All Historical Programs 2021 30 Number of “Major” Pipeline Programs G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Ginkgo is creating the industry standard ecosystem Like other horizontal tech platforms, Ginkgo is building a strong developer community - wrapping services around the platform to drive industry growth and, ultimately, demand Launched Ginkgo Ferment, our annual conference, in 2018 VIEW KEYNOTE Other leading developer conferences 31 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Ginkgo is creating the industry standard ecosystem Like other horizontal tech platforms, Ginkgo is building a strong developer community - wrapping services around the platform to drive industry growth and, ultimately, demand Launched Ginkgo Ferment, our annual conference, in 2018 VIEW KEYNOTE Other leading developer conferences 31 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

REGULATORY We will be greatly expanding our ecosystem of services for cell programmers running on the Ginkgo platform Ginkgo annual developer Open-source conference and product Source of innovative bioengineering tools showcase technologies for industry partners: hub for investment, Help drive legislative acquisition, and partnership change for novel categories Mature manufacturing network across industries w/ clean tech-transfer protocols Help clients file patents / protect IP Biosecurity ESG Capital Access + Foundry Credits Ferment Consortium 32 COMMUNITY G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021REGULATORY We will be greatly expanding our ecosystem of services for cell programmers running on the Ginkgo platform Ginkgo annual developer Open-source conference and product Source of innovative bioengineering tools showcase technologies for industry partners: hub for investment, Help drive legislative acquisition, and partnership change for novel categories Mature manufacturing network across industries w/ clean tech-transfer protocols Help clients file patents / protect IP Biosecurity ESG Capital Access + Foundry Credits Ferment Consortium 32 COMMUNITY G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program adds predictable near-term revenue from usage fees and provides Ginkgo upside through value share. 33 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program adds predictable near-term revenue from usage fees and provides Ginkgo upside through value share. 33 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed programs Foundry Royalty Stream Equity Equity represents the risk- adjusted NPV of a potential royalty stream OR … … … … Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 0 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Highly predictable revenue Cash flows from value share are typically 100% contribution margin stream independent of as Ginkgo incurs minimal ongoing support or delivery costs program success The choice to structure downstream economics as royalties or equity is typically based on customer size Note: Illustrative economics; variation exists between programs 34 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed programs Foundry Royalty Stream Equity Equity represents the risk- adjusted NPV of a potential royalty stream OR … … … … Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 0 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Highly predictable revenue Cash flows from value share are typically 100% contribution margin stream independent of as Ginkgo incurs minimal ongoing support or delivery costs program success The choice to structure downstream economics as royalties or equity is typically based on customer size Note: Illustrative economics; variation exists between programs 34 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Program unit economics are strong and improving FOUNDRY USAGE FEES DOWNSTREAM VALUE CAPTURE Foundry Downstream Value Ginkgo receives downstream value in multiple forms. The equity Ginkgo has steadily increased the portion of program value per program provides context for the future value. R&D costs that are covered upfront by customers 54 120% 100% (2) Adj. for Free COVID Services Ginkgo will recognize royalty % Direct Cost Coverage Royalty / revenues over time as 100% Other 80% programs are completed These should be 20 and commercialized roughly equivalent in value over the long- 80% run, but royalties take 60% longer to materialize The current equity value of 60% our major programs is 40% over $500M (3) Equity 40% 34 …representing an average of 20% $15M per program 20% 0% 0% Major Programs 14-15 16-17 18-19 2020 (2017-2020) Year Deal Signed (1) Represents cumulative revenues from 2017-2020 for programs signed in the relevant year(s) divided by the total program expenses in 2017-2020 (2) Adjusts out expenses associated with programs Ginkgo performed under our free $25M commitment to COVID programs in spring 2020 35 (3) Includes one program for publicly-traded Cronos which is structured as a lump-sum equity payment upon delivery (1) % Cost Coverage of Programs Number of Major Programs Initiated G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Program unit economics are strong and improving FOUNDRY USAGE FEES DOWNSTREAM VALUE CAPTURE Foundry Downstream Value Ginkgo receives downstream value in multiple forms. The equity Ginkgo has steadily increased the portion of program value per program provides context for the future value. R&D costs that are covered upfront by customers 54 120% 100% (2) Adj. for Free COVID Services Ginkgo will recognize royalty % Direct Cost Coverage Royalty / revenues over time as 100% Other 80% programs are completed These should be 20 and commercialized roughly equivalent in value over the long- 80% run, but royalties take 60% longer to materialize The current equity value of 60% our major programs is 40% over $500M (3) Equity 40% 34 …representing an average of 20% $15M per program 20% 0% 0% Major Programs 14-15 16-17 18-19 2020 (2017-2020) Year Deal Signed (1) Represents cumulative revenues from 2017-2020 for programs signed in the relevant year(s) divided by the total program expenses in 2017-2020 (2) Adjusts out expenses associated with programs Ginkgo performed under our free $25M commitment to COVID programs in spring 2020 35 (3) Includes one program for publicly-traded Cronos which is structured as a lump-sum equity payment upon delivery (1) % Cost Coverage of Programs Number of Major Programs Initiated G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

Key Financial Metrics (1) ($M) 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $64 $100 $175 $341 $628 $1,099 % growth 18% 57% 75% 95% 84% 75% GAAP adjustments not projected memo: GAAP Adjustments ($4) Foundry Revenue (GAAP) $59 $100 $175 $341 $628 $1,099 Emerging business, projections not provided (+) Biosecurity $17 $50 Total GAAP Revenue $77 $150 $175 $341 $628 $1,099 (1) Adjusted EBITDA ($121) ($157) ($156) ($136) ($47) $166 (2) Capital Expenditures ($72) ($66) ($118) ($146) ($193) ($234) PLUS 2017-2020 2021 2022 2023 2024 2025 20 34 # New Programs 23 60 136 268 508 Royalty Equity 54 % growth 157% 127% 97% 90% Increases if: p(success) increases, value of programs increases (3) Risk-Adjusted NPV / Program ~$15M Decreases if: lower take rates, value of programs decreases # New Programs × NPV / Program (3) NPV of New Programs Signed ~$500M (1) See Investor Presentation for a reconciliation of Net Income to Adjusted EBITDA for historical periods presented (2) 2020 CapEx of $72M includes $14M of CapEx that is included in Accounts Payable and Accrued Expenses at 12/31/2020 (3) Based on management estimate of the average current equity value of our cumulative major programs from 2017 to 2020 36 Key Program Metrics Foundry P&L G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021Key Financial Metrics (1) ($M) 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $64 $100 $175 $341 $628 $1,099 % growth 18% 57% 75% 95% 84% 75% GAAP adjustments not projected memo: GAAP Adjustments ($4) Foundry Revenue (GAAP) $59 $100 $175 $341 $628 $1,099 Emerging business, projections not provided (+) Biosecurity $17 $50 Total GAAP Revenue $77 $150 $175 $341 $628 $1,099 (1) Adjusted EBITDA ($121) ($157) ($156) ($136) ($47) $166 (2) Capital Expenditures ($72) ($66) ($118) ($146) ($193) ($234) PLUS 2017-2020 2021 2022 2023 2024 2025 20 34 # New Programs 23 60 136 268 508 Royalty Equity 54 % growth 157% 127% 97% 90% Increases if: p(success) increases, value of programs increases (3) Risk-Adjusted NPV / Program ~$15M Decreases if: lower take rates, value of programs decreases # New Programs × NPV / Program (3) NPV of New Programs Signed ~$500M (1) See Investor Presentation for a reconciliation of Net Income to Adjusted EBITDA for historical periods presented (2) 2020 CapEx of $72M includes $14M of CapEx that is included in Accounts Payable and Accrued Expenses at 12/31/2020 (3) Based on management estimate of the average current equity value of our cumulative major programs from 2017 to 2020 36 Key Program Metrics Foundry P&L G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

The most powerful technologies require the most care Our culture is built on care, transparency, diversity, employee ownership and a deep, humble respect for biology. We take care in considering which programs we pursue We invest in our and which we do not, and explore the implications of biotechnologies through many forums, including our communities and their magazine: GROW biosecurity as well as robust ESG practices. READ MORE ABOUT: • The meaning of nature after biotechnology • The legacy of eugenics in beauty • The role of the philosopher in the life sciences • The potential for synthetic biology to save coral reefs • The impact of the pandemic on scientists and science 37 G G II N N K K G G O O B B II OWO OWO R R K K SS R A Y MO N D J A ME S | J UN E 2021The most powerful technologies require the most care Our culture is built on care, transparency, diversity, employee ownership and a deep, humble respect for biology. We take care in considering which programs we pursue We invest in our and which we do not, and explore the implications of biotechnologies through many forums, including our communities and their magazine: GROW biosecurity as well as robust ESG practices. READ MORE ABOUT: • The meaning of nature after biotechnology • The legacy of eugenics in beauty • The role of the philosopher in the life sciences • The potential for synthetic biology to save coral reefs • The impact of the pandemic on scientists and science 37 G G II N N K K G G O O B B II OWO OWO R R K K SS R A Y MO N D J A ME S | J UN E 2021

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We hope… …that when technology meets biology, life finds a way. Anna Marie Wagner, SVP Corporate Development annamarie@ginkgobioworks.com 38 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We hope… …that when technology meets biology, life finds a way. Anna Marie Wagner, SVP Corporate Development annamarie@ginkgobioworks.com 38 G I N K G O B I OWO R K S R A Y MO N D J A ME S | J UN E 2021

ADDITIONAL LEGAL INFORMATION Forward-Looking Statements Legend This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo Bioworks, Inc. (“Ginkgo Bioworks”) and Soaring Eagle Acquisition Corp. (“SRNG”), including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the services offered by Ginkgo Bioworks and the markets in which it operates, and Ginkgo Bioworks’ projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of SRNG’s securities, (ii) the risk that the transaction may not be completed by SRNG’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SRNG, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of SRNG and Ginkgo Bioworks, the satisfaction of the minimum trust account amount following redemptions by SRNG’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Ginkgo Bioworks’ business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Ginkgo Bioworks and potential difficulties in Ginkgo Bioworks employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Ginkgo Bioworks or against SRNG related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of SRNG’s securities on Nasdaq, (x) volatility in the price of SRNG’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo Bioworks plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo Bioworks’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of SRNG’s proxy statement/prospectus relating to the Business Combination, and in SRNG’s other filings with the Securities and Exchange Commission (the “SEC”). SRNG and Ginkgo Bioworks caution that the foregoing list of factors is not exclusive. SRNG and Ginkgo Bioworks caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SRNG nor Ginkgo Bioworks undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Additional Information and Where to Find It This document relates to a proposed transaction between Ginkgo Bioworks and SRNG. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. SRNG intends to file a registration statement on Form S-4 that will include a proxy statement of SRNG and a prospectus of SRNG. The proxy statement/prospectus will be sent to all SRNG and Ginkgo Bioworks stockholders. SRNG also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of SRNG and Ginkgo Bioworks are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by SRNG through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by SRNG may be obtained free of charge by written request to SRNG at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310) 209-7280. Participants in Solicitation SRNG’s and Ginkgo Bioworks and their respective directors and officers may be deemed to be participants in the solicitation of proxies from SRNG’s stockholders in connection with the proposed transaction. Information about SRNG’s directors and executive officers and their ownership of SRNG’s securities is set forth in SRNG’s filings with the SEC. To the extent that holdings of SRNG’s securities have changed since the amounts printed in SRNG’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.ADDITIONAL LEGAL INFORMATION Forward-Looking Statements Legend This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Ginkgo Bioworks, Inc. (“Ginkgo Bioworks”) and Soaring Eagle Acquisition Corp. (“SRNG”), including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the services offered by Ginkgo Bioworks and the markets in which it operates, and Ginkgo Bioworks’ projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of SRNG’s securities, (ii) the risk that the transaction may not be completed by SRNG’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SRNG, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of SRNG and Ginkgo Bioworks, the satisfaction of the minimum trust account amount following redemptions by SRNG’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Ginkgo Bioworks’ business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Ginkgo Bioworks and potential difficulties in Ginkgo Bioworks employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Ginkgo Bioworks or against SRNG related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of SRNG’s securities on Nasdaq, (x) volatility in the price of SRNG’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo Bioworks plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo Bioworks’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of SRNG’s proxy statement/prospectus relating to the Business Combination, and in SRNG’s other filings with the Securities and Exchange Commission (the “SEC”). SRNG and Ginkgo Bioworks caution that the foregoing list of factors is not exclusive. SRNG and Ginkgo Bioworks caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SRNG nor Ginkgo Bioworks undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Additional Information and Where to Find It This document relates to a proposed transaction between Ginkgo Bioworks and SRNG. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. SRNG intends to file a registration statement on Form S-4 that will include a proxy statement of SRNG and a prospectus of SRNG. The proxy statement/prospectus will be sent to all SRNG and Ginkgo Bioworks stockholders. SRNG also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of SRNG and Ginkgo Bioworks are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by SRNG through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by SRNG may be obtained free of charge by written request to SRNG at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310) 209-7280. Participants in Solicitation SRNG’s and Ginkgo Bioworks and their respective directors and officers may be deemed to be participants in the solicitation of proxies from SRNG’s stockholders in connection with the proposed transaction. Information about SRNG’s directors and executive officers and their ownership of SRNG’s securities is set forth in SRNG’s filings with the SEC. To the extent that holdings of SRNG’s securities have changed since the amounts printed in SRNG’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.